IMMUNOASSAY FOR GLYCOSYLATED HEMOGLOBIN

促进糖尿病的诊断和治疗 患者血清糖化血红蛋白的测定。 糖尿病患者体内这种分子的相对水平升高 有耐心的。目前可用于这些测量的方法 都很耗时，需要相当多的技术专长。 在这里提出的工作中，我们计划产生单克隆 针对糖基化残基的特异性抗体 血红蛋白。这将通过免疫三只小鼠来完成。 不同类型的免疫原：纯化的糖化血红蛋白， 糖化血红蛋白衍生的多肽，然后 与免疫原性载体蛋白偶联，并纯化 糖肽与脂类结合。这些将被注入 与各种佐剂一起演唱会产生小鼠 分泌单抗的杂交瘤 区分这两种形式的血红蛋白。这些抗体将 用于建立检测糖基化的“三明治”酶联免疫吸附试验 病人样本中的血红蛋白。在第二阶段研究中， 这种分析的开发将完成，光学和 使用临床材料进行验证和评估。

Diagnosis and management of diabetes melitus is facilitated measurements of glycosylated hemoglobin in patient serum. Relative levels of this molecule are elevated in the diabetic patient. The presently available methods for these measurements are time consuming and require considerable technical expertise. In the work proposed here, we plan to generate monoclonal antibodies specific for the glycosylated residue on glycosylated hemoglobin. This will be accomplished by immunizing mice three different types of immunogen: purified glycosylated hemoglobin, peptides derived from glycosylated hemoglobin and then conjugated to immunogenic carrier proteins, and purified glycopeptides conjugated to lipids. These will be injected in concert with a variety of adjuvants to generate murine hybridomas secreting monoclonal antibodies capable of distinguishing the two forms of hemoglobin. These antibodies will be used to develop a "sandwich" ELISA for measuring glycosylated hemoglobin in patient samples. In Phase II studies, the development of this assay will be completed, optomized and validated, and evaluated using clinical material.